Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.
- DOI
- 10.3389/fphar.2026.1986842
- Published
- 2026
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1986842,
title = {Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.},
author = {Maletin N and Denda N and Paut Kusturica M and Rašković A and Babović S and Golušin Z},
year = {2026},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2026.1986842},
url = {https://doi.org/10.3389/fphar.2026.1986842}
}RIS
TY - JOUR TI - Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations. AU - Maletin N AU - Denda N AU - Paut Kusturica M AU - Rašković A AU - Babović S AU - Golušin Z PY - 2026 JO - Frontiers in pharmacology DO - 10.3389/fphar.2026.1986842 UR - https://doi.org/10.3389/fphar.2026.1986842 ER -
APA
N, M., N, D., M, P. K., A, R., S, B., & Z, G. (2026). Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1986842